Cantargia — Board/Management Information 2020

Dec 21, 2020

Press release

Cantargia AB 556791-6019 21 December 2020

Changes to Cantargia's nomination committee

In October 2020, Cantargia's AB (publ) nomination committee ahead of the 2021 annual general meeting was appointed in accordance with the guidelines established by the 2020 annual general meeting, Today, Cantargia announces that the committee member Alexander Mata (appointed by Alecta Pensionsförsäkring, Ömsesidigt) resigns from the nomination committee and that Alecta Pensionsförsäkring, Ömsesidigt has appointed Mikael Wiberg as a new member.

Going forward, the nomination committee comprises Marianne Nilsson (Swedbank Robur Fonder), Jannis Kitsakis (Fjärde APfonden), Mikael Wiberg (Alecta Pensionsförsäkring, Ömsesidigt) and Magnus Persson (chairman of the board).

For further information, please contact:

Magnus Persson, chairman of the board and member of the nomination committee. Telephone: +46 (0)737 314146 E-mail: magnus.modee.persson@gmail.com

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for lifethreatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied clinically as combination therapy with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy show a higher response rate than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA).

More information about Cantargia is available at www.cantargia.com.